Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19

计划入组 156 人 · 首次发布于 2022 年 1 月 11 日

Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19

计划入组 984 人 · 首次发布于 2023 年 3 月 24 日

Pycnogenol® in Post-COVID-19 Condition

计划入组 153 人 · 首次发布于 2023 年 6 月 6 日

X-Synergy®

NanoLithium® NP03

Integra®-SC

19 and Pacific, LLC

United States

GENOMIC HEALTH, INC.

United States

TEXAS RETINA ASSOCIATES

United States

Greenyn Biotechnology's Insumate® mcIRBP-19 Bitter Melon Peptide Achieves Triple Certification for Metabolic Health

ViroGates and Sobi Expand Collaboration on suPARnostic® Diagnostic for Kineret® Treatment

Fresenius Kabi Launches Tyenne®, Canada's First Tocilizumab Biosimilar for Autoimmune Conditions